Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell (Treg) therapies for various indications, filed on Friday with the SEC to raise up to $17 million in an initial public offering.
The company is developing numerous Treg-based therapies focused on neurodegenerative, autoimmune, and metabolic diseases. Coya Therapeutics' sole clinical-stage candidate, COYA 101, is an autologous cell therapy for the treatment of ALS. COYA 101 completed a Phase 2a clinical trial in May 2021, and the company plans to begin a Phase 2b trial in the 1H24.
The Houston, TX-based company was founded in 2020 and plans to list on the Nasdaq under the symbol COYA. Coya Therapeutics filed confidentially on August 19, 2022. Chardan Capital Markets and Newbridge Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
